Madrigal Pharma (MDGL) Tops Q1 EPS by 94c

Madrigal Pharma (NASDAQ: MDGL) reported Q1 EPS of ($3.25), $0.94 better than the analyst estimate of ($4.19). Revenue for the quarter came in at $311.34 million versus the consensus estimate of $301.29 million.

For earnings history and earnings-related data on Madrigal Pharma (MDGL) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Trump: 40-60% of chip manufacturing will be in the U.S. - CNBC Interview
• Raymond James Upgrades Aecon Group (ARE:CN) (AEGXF) to Outperform